Meeting
2013 ASCO Annual Meeting
Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC).
Authors
Hui Zhu
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Hui Zhu , Andria Valeria Arrossi , Paul Elson , Carol Farver , Raymond R. Tubbs , Sudish C. Murthy , David P. Mason , Peter J. Mazzone , Nathan A. Pennell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8113)
DOI
10.1200/jco.2013.31.15_suppl.8113
Abstract #
8113
Poster Bd #
41E
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
First Author: Joel W. Neal
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2015 ASCO Annual Meeting
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients.
First Author: Antonio Marchetti
First Author: Karen L. Reckamp